Metraipolis › archive › dc_2f4fc5daa2f0
Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease — Europe PMC PPR:PPR264253
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR264253
- DOI
- 10.1101/2021.01.12.426388
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-06T10:01:44.517Z
- SHA-256 of the archived text
5d405beb96aff9f84d05ae53c7658aae5aebba68e9eea1dbf4c8464fff6c03d0- Stable URL of this page
https://metraipolis.com/documento/dc_2f4fc5daa2f0
How to cite
Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease — Europe PMC PPR:PPR264253 — Europe PMC, https://europepmc.org/article/PPR/PPR264253 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2f4fc5daa2f0 (Metraipolis archive dc_2f4fc5daa2f0, sha256 5d405beb96aff9f84d05ae53c7658aae5aebba68e9eea1dbf4c8464fff6c03d0)
BibTeX
@misc{dc2f4fc5daa2f0,
title = {Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease — Europe PMC PPR:PPR264253},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR264253},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2f4fc5daa2f0; sha256 5d405beb96aff9f84d05ae53c7658aae5aebba68e9eea1dbf4c8464fff6c03d0},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR264253. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
ABSTRACT: The main protease (3CL M pro ) from SARS-CoV-2, the virus that causes COVID-19, is an essential enzyme for viral replication with no human counterpart, making it an attractive drug target. Although drugs have been developed to inhibit the proteases from HIV, hepatitis C and other viruses, no such therapeutic is available to inhibit the main protease of SARS-CoV-2. To directly observe the protonation states in SARS-CoV-2 M pro and to elucidate their importance in inhibitor binding, we determined the structure of the enzyme in complex with the α-ketoamide inhibitor telaprevir using neutron protein crystallography at near-physiological temperature. We compared protonation states in the inhibitor complex with those determined for a ligand-free neutron structure of M pro . This comparison revealed that three active-site histidine residues (His41, His163 and His164) adapt to ligand binding, altering their protonation states to accommodate binding of telaprevir. We suggest that binding of other α-ketoamide inhibitors can lead to the same protonation state changes of the active site histidine residues. Thus, by studying the role of active site protonation changes induced by inhibitors we provide crucial insights to help guide rational drug design, allowing precise tailoring of inhibitors to manipulate the electrostatic environment of SARS-CoV-2 M pro . Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: bioRxiv, 2021 (prima pubblicazione 2021-01-12). Identificativi: DOI 10.1101/2021.01.12.426388. Pagina: https://europepmc.org/article/PPR/PPR264253 — https://doi.org/10.1101/2021.01.12.426388. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-06T09:57:34.317Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.